Empowering scientists to build biotech startups. Supporting large organizations in global innovation and expansion, with expertise in cell and gene therapy. DEI advocate and emotional intelligence champion
Can you figure out the missing piece here? Just as Next-Generation Sequencing (#NGS) revolutionized #PrecisionMedicine, the question now is:? ???????? ???????? ???? ?????? ????????-?????????????? ???????? ?????????????? #?????????????????????? ???? ????????????? NGS transformed healthcare by making genome sequencing faster, cheaper, and more accurate. Unlike the older Sanger method, which sequenced DNA one fragment at a time, NGS analyses millions of fragments simultaneously. This breakthrough reduced sequencing costs from billions to under $500 per genome today. Platforms like Illumina’s NovaSeq X and Oxford Nanopore’s long-read sequencing systems are driving ???????????? ???????????????????? ?????? ???????????????? ???????????????? The impact of NGS is undeniable. It enabled precision medicine to tailor treatments to individual genetic profiles, leading to better disease prevention, improved drug efficacy, and significant advancements in cancer and rare disease treatments. Today, precision medicine accounts for over 25% of FDA-approved drugs. Now let’s turn to cell therapy—a sector projected to grow to $20 billion by 2030. Startups like Arsenal Biosciences, Inc. (raised $325M in 2024) and Capstan Therapeutics (raised $ 175M in 2024) are only two examples of leading cell therapy companies which are reshaping medicine. Yet challenges persist: high costs, complex logistics, and scalability issues. Companies like #Novartis, #Roche, #Pfizer, #Bayer, #JnJ, #BMS, #AstraZeneca have heavily invested in both precision medicine and cell therapy So, here’s the big question:? ????????’?? ?????? ?????????????? ?????????? ???????? ?????????? ?????????????????????????? ???????? ?????????????? ?????????????????????????? ?????? ???????????? ?????? ?????????????????? ???????????? ?????????? ?????????????? ?????????????????????? ?????? ????????????????? Could it be AI, or something we haven’t thought of yet? ?????????? ???? ?????? ?????????????? ???????? #??????????????????????????????????????????? ???????.. This is part of what I’ll be diving into in #2025. If you’re an #investor, #technologydeveloper, or #celltherapydeveloper, let’s connect and explore how we can shape the next wave of biotech together. #Biotech #NGS #CellTherapy #Innovation #HealthcareTransformation #PrecisionMedicine
Sapna Tandon, MD
2 个月
Dr Fabio D'Agostino one area of NGS application in cell therapy manufacturing is Analyzing the genetic profile of donor cells to identify any pre-existing mutations or variations that could impact the therapy as well as viral vector analysis in gene therapy . NGS can be used to characterize the viral vectors used to deliver genetic material, checking for potential contaminations or mutation. Given safety concerns around these therapies.
To me there should be two question marks on the right side; (i) The next generation gene editing technology platform (arguably CRISPR technology is the one). (ii) The next generation cell delivery/regulation of the gene editing (we still working on this part).
Carl Schoellhammer
2 个月
Lots of room for novel tools. They largely exist today but are difficult to apply in a regulated, rapid, robust manufacturing process.
AI might be the missing link for cell therapy's next big move. It's exciting to think about.
Dan Strange
2 个月
I'm not sure it will happen in a single leap - you mention NGS, (which did have a dramatic impact) but sequencing costs continued to fall by several orders of magnitude following its invention and will likely continue to do fall. I think it will be similar in cell therapy - there will be a few paradigm shifts (and I believe that l robotic manufacturing enabling true full automation may be one of them), but also a lot of gradual improvements across the full manufacturing process and cell therapy ecosystem that drive down cost and improve quality over time, which is why it's important that future manufacturing platforms can leverage these gains. And with regards to AI completly agree we need to collect the right data first, but also think that will come as fuller automation alongside better analytics starts playing a role.
Jack Beierle
2 个月
Methods for deep phenotyping/characterization and live cell isolation/purification. AI guided in a marker free format. Narwhal Bio Inc. has methods for this.
Cenk Sumen
2 个月
That’s a great perspective Fabio. I would propose: “scalable cell selection and editing” ??
Matthew Prout
2 个月
I appreciate your concise statement of the problem, and I couldn’t agree more about the unmet need. There are some differences in patient outcomes that make it more challenging to match the success of precision medicine. When a single cell in a treatment cohort can have side effects such as autoimmune disease, GVH, and ultimately death, we need to consider the resolution of our data and its depth. Yes, the solution will have to scale with high precision, but consider where sequencers are placed. Placing a device that provides deep per-cell data at the endpoints would be the closest parallel to Illumina’s impact on precision medicine.
Empowering scientists to build biotech startups. Supporting large organizations in global innovation and expansion, with expertise in cell and gene therapy. DEI advocate and emotional intelligence champion
2 个月And I know what you’re thinking—NGS is already widely used in cell therapy (just look at examples like Kite, Allogene, and Sangamo). That’s absolutely true, and its impact goes far beyond precision medicine. But when it comes to transforming cell therapy manufacturing, NGS alone isn’t the game-changer.